Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
CanadaIPO:
29 October 2019Website:
http://www.profoundmedical.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PROF Latest News
Profound Medical Corp. will provide a business update at the 2024 Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
Profound Medical Corp. (NASDAQ:PROF ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer Rashed Dewan – Chief Financial Officer Mathieu Burtnyk – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Rahul Sarugaser – Raymond James Michael Sarcone – Jefferies Brian Gagnon – Gagnon Securities Chris Potter – Northern Border Investments Operator Good day, and welcome to the Profound Medical Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The mean of analysts' price targets for Profound Medical (PROF) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Profound Medical Corp. (NASDAQ:PROF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - Chairman and CEO Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Benjamin Haynor - Alliance Global Partners Nelson Cox - Lake Street Capital Markets Scott McAuley - Paradigm Capital Operator Good day and thank you for standing by. Welcome to the Profound Medical Third Quarter 2023 Financial Results Conference Call.
TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2023 financial results after market close on Thursday, November 2, 2023.
TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 4:55 p.m. Eastern Time in NYC.
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical Corp. (NASDAQ:PROF ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Nelson Cox - Lake Street Capital Markets Ben Haynor - Alliance Global Partners Joshua Jennings - TD Cowen Operator Good day and thank you for standing by. Welcome to the Profound Medical Second Quarter 2023 Financial Results Conference Call.
What type of business is Profound Medical?
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
What sector is Profound Medical in?
Profound Medical is in the Healthcare sector
What industry is Profound Medical in?
Profound Medical is in the Medical Devices industry
What country is Profound Medical from?
Profound Medical is headquartered in Canada
When did Profound Medical go public?
Profound Medical initial public offering (IPO) was on 29 October 2019
What is Profound Medical website?
https://www.profoundmedical.com
Is Profound Medical in the S&P 500?
No, Profound Medical is not included in the S&P 500 index
Is Profound Medical in the NASDAQ 100?
No, Profound Medical is not included in the NASDAQ 100 index
Is Profound Medical in the Dow Jones?
No, Profound Medical is not included in the Dow Jones index
When does Profound Medical report earnings?
The next expected earnings date for Profound Medical is 09 August 2024